| ABC | Abacavir |
| AIDS | Acquired Immundeficiency Syndrome |
| APRI | AST to Platelet Ratio Index |
| ART | Antiretroviral therapy |
| BL | Baseline |
| DAA | Direct-acting antiviral |
| DAC | Daclatasvir |
| EL | Elbasvir |
| EOT | End of therapy |
| FIB-4 | Fibrosis-4 |
| FTC | Emtricitabine |
| GLE | Glecaprevir |
| GRZ | Grazoprevir |
| HCC | Hepatocellular carcinoma |
| HCV | Hepatitis C virus |
| HIV | Human Immunodeficiency virus |
| IDU | Inject drug users |
| IFN | Interferon |
| INSTI | Integrase inhibitors |
| LED | Ledipasvir |
| MSM | Men who have sex with men |
| NRTI | Nucleoside reverse transcriptase inhibitors |
| NNRTI | Non-nucleoside reverse transcripatse inhibitors |
| PI | Protease inhibitors |
| PBR | Pibrentasvir |
| PLWHIV | People living with HIV |
| SOF | Sofosbuvir |
| SVR | Sustained virological response |
| TAF | Tenofovir alafenamide |
| TDF | Tenofovir disoproxil fumarate |
| VEL | Velpatasvir |
| 3D | Ombitasvir/paritaprevir/ritonavir + dasabuvir |
| 3TC | Lamivudine |